Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Lymphoma 34Leukemia 34Lymphoma, Follicular 27Melanoma 25Leukemia, Lymphocytic, Chronic, B-Cell 22Precursor Cell Lymphoblastic Leukemia-Lymphoma 21Lymphoma, Non-Hodgkin 20Leukemia, Myeloid, Acute 20Multiple Myeloma 18Breast Neoplasms 18Lymphoma, Large B-Cell, Diffuse 17Prostatic Neoplasms 15Lymphoma, Mantle-Cell 15Lymphoma, Large-Cell, Immunoblastic 15Neuroblastoma 14Neoplasms, Plasma Cell 13Myelodysplastic Syndromes 13Leukemia, Myelogenous, Chronic, BCR-ABL Positive 13Hodgkin Disease 13Burkitt Lymphoma 13Leukemia, Myeloid, Chronic-Phase 12Neoplasm Metastasis 11Lymphoma, B-Cell, Marginal Zone 11Lung Neoplasms 10Glioblastoma 9Carcinoma, Non-Small-Cell Lung 9Myeloproliferative Disorders 8Leukemia, Myeloid, Accelerated Phase 8Ovarian Neoplasms 7Gliosarcoma 7

Interventions

sargramostim 1Granulocyte-Macrophage Colony-Stimulating Factor 1Granulocyte Colony-Stimulating Factor 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Transplant-Related Hematologic Malignancy × sargramostim × Clear all
NCT04237623 2026-04-16

GM-CSF With Post-Transplant Cyclophosphamide

Northside Hospital, Inc.

Phase 2 Recruiting
38 enrolled

Transplant-Related Hematologic Malignancy

Data powered by HemOnc (CC BY 4.0) Colophon âš¡